Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Vera Therapeutics Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results August 08, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 05, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer July 01, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Appoints Christy J. Oliger to Board of Directors June 11, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 07, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) May 28, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress May 25, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results May 09, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 07, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress April 02, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results March 20, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference February 28, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 02, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock February 01, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock January 29, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock January 29, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy January 25, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer January 08, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024 January 08, 2024 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference December 27, 2023 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results November 09, 2023 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 November 04, 2023 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Scheduled to Present at November Investor Conferences October 30, 2023 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting October 13, 2023 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Scheduled to Present at September Investor Conferences August 31, 2023 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results August 10, 2023 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress June 17, 2023 From Vera Therapeutics Via GlobeNewswire Tickers VERA Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN June 15, 2023 From Vera Therapeutics Via GlobeNewswire Tickers VERA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.